Dasatinib News and Research

RSS
Dasatinib is an orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. Dasatinib binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, dasatinib has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.
New system for anti-cancer drug delivery offers hope to treat pediatric tumors

New system for anti-cancer drug delivery offers hope to treat pediatric tumors

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Interfering with enzyme's movement may be new approach for developing of anti-cancer drugs

Researchers test new cancer research model that may reduce cost and speed up studies

Researchers test new cancer research model that may reduce cost and speed up studies

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Mayo Clinic study reveals link between senescent cells and bone loss in mice

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Novel approach to leukemia therapy can safely improve treatment success, reduce side effects

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic researchers discover three new senolytic drugs

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Mayo Clinic study finds link between biology of aging and idiopathic pulmonary fibrosis

Research findings point to inherited genetic basis of ALL risk in children

Research findings point to inherited genetic basis of ALL risk in children

Salvage alloSCT remains option for progressing CML patients

Salvage alloSCT remains option for progressing CML patients

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Maintenance TKI therapy 'feasible' for high-risk CML patients after allogeneic HSCT

Long-term dasatinib findings support first-line use in CML

Long-term dasatinib findings support first-line use in CML

Real-world CML management in line with ELN guidelines

Real-world CML management in line with ELN guidelines

CML treatment-free remission criteria outlined

CML treatment-free remission criteria outlined

BCR-ABL halving time indicates CML prognosis during front-line TKI

BCR-ABL halving time indicates CML prognosis during front-line TKI

Vascular events in CML may not be linked to TKI therapy

Vascular events in CML may not be linked to TKI therapy

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

Vascular Occlusion Risk Reviewed For CML New-Generation TKIs

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

CNIO researchers reveal how combination of dasatinib and demcizumab reduces lung adenocarcinomas

BCR–ABL transcript type linked to TKI response, outcomes

BCR–ABL transcript type linked to TKI response, outcomes

Positive bosutinib response for elderly blast phase CML patient

Positive bosutinib response for elderly blast phase CML patient

Cardiovascular considerations crucial for CML TKI patients

Cardiovascular considerations crucial for CML TKI patients